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Abstract
Antibodies generated against West Nile virus (WNV) during infection are essential for controlling dissemination. Recent 
studies have demonstrated that epitopes in all three domains of the flavivirus envelope protein (E) are targets for 
neutralizing antibodies, with determinants in domain III (DIII) eliciting antibodies with strong inhibitory properties. In 
order to increase the magnitude and quality of the antibody response against the WNV E protein, DNA vaccines with 
derivatives of the WNV E gene (full length E, truncated E, or DIII region, some in the context of the pre-membrane [prM] 
gene) were conjugated to the molecular adjuvant P28. The P28 region of the complement protein C3d is the minimum 
CR2-binding domain necessary for the adjuvant activity of C3d. Delivery of DNA-based vaccines by gene gun and 
intramuscular routes stimulated production of IgG antibodies against the WNV DIII region of the E protein. With the 
exception of the vaccine expressing prM/E given intramuscularly, only mice that received DNA vaccines by gene gun 
produced protective neutralizing antibody titers (FRNT80 titer >1/40). Correspondingly, mice vaccinated by the gene 
gun route were protected to a greater level from lethal WNV challenge. In general, mice vaccinated with P28-adjuvated 
vaccines produced higher IgG titers than mice vaccinated with non-adjuvanted vaccines.
Introduction
West Nile virus (WNV) is a single-stranded positive
polarity enveloped RNA virus and member of the Flavivi-
rus genus of the Flaviviridae family. The genome (11 kb)
encodes for three structural proteins (Capsid [C] [1], pre-
membrane [prM] that is cleaved to form a mature mem-
brane [M] [2] and Envelope [E] [1]) and seven nonstruc-
tural gene products (NS1, 2A, 2B, 3, 4A, 4B and 5). WNV
is transmitted by mosquitoes and causes morbidity and
mortality in birds, horses, and humans. Since 1999, there
have been over 29,000 cases that reached clinical atten-
tion and resulted in greater than a thousand deaths http:/
/www.cdc.gov/ncidod/dvbid/westnile/surv&control.htm
within the United States as reported to the Centers for
Disease Control and Prevention. As the geographic distri-
bution of this virus continues to expand, naïve human
populations are put at greater risk, making the need for a
licensed vaccine and/or antiviral treatment pressing [3].
The host immune response is critical for limiting virus
spread and disease. Results from genetically engineered
mice indicate that both the innate (e.g., interferon) and
the adaptive (B and T cells) immune responses control
WNV infection [4]. The production of antibodies is
essential to protection against WNV infection [5], and
passive antibody transfer of anti-WNV neutralizing anti-
bodies can prevent or treat lethal infection [6]. The pri-
mary target of the neutralizing antibody response is the E
protein, which is the most accessible structural glycopro-
tein on the surface of the virion [7]. Structural analysis of
the soluble ectodomain of flavivirus E proteins reveals
three domains [8,9]. Domain I is an 8-stranded β-barrel
that participates in the conformational changes associ-
ated with the acidification of the endosome. Domain II,
which contains 12 β-strands, has important roles in
dimerization, trimerization, and virus-mediated fusion
[10-12]. Domain III adopts an immunoglobulin-like fold
that contains the most distal projecting loops on the
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mature virion [13,14], and has been hypothesized to con-
tain a binding site for cell attachment [15]. Even though
neutralizing antibodies are generated against epitopes in
all three domains, many highly neutralizing antibodies
cluster to epitopes in DIII [16].
Our laboratory and others have demonstrated that the
fusion of C3d to an antigen results in enhanced immuno-
genicity of the fused antigen
[5,16,17,19,21,24,31,32,35,36]. C3d is the final degrada-
tion product of the third component of complement (C3).
The most commonly proposed mechanisms for C3d
adjuvanticity involves C3d binding to the complement
receptor 2 (CR2) that is located on the surface of follicu-
lar dendritic cells (FDC), B cells, and T cells in many spe-
cies (for review, see [17]). C3d stimulates antigen
presentation by FDCs and helps to maintain immunolog-
ical B cell memory. On B cells, C3d interacts with CR2,
CD19 and CD81 surface molecules. CD19 has a long
intracellular tail that triggers a signaling cascade that
results in cell activation and proliferation. Simultaneous
ligation of CR2 by C3d and surface immunoglobulin by
antigen activates two signaling pathways that synergize to
activate B cells, thereby leading to enhanced antibody
secretion against the fused antigen. Multimers of a 28
amino acid peptide of C3d (P28), which contains the pre-
dicted minimum CR2 binding domain, have been demon-
strated to have similar adjuvant properties as the entire
C3d molecule [18]. The P28 molecule is ~9% the size of
the entire C3d molecule and therefore, is an attractive
adjuvant to elicit enhanced B cell responses to a vaccine
antigen.
Currently, there are no effective anti-WNV treatments
and there are no Food and Drug Administration (FDA)-
licensed vaccines for humans. The FDA has approved a
WNV vaccine for horses and other exotic animals, based
upon a formalin-inactivated killed virus (WNV Innova-
tor™, Fort Dodge Animal Health), but these require
annual boosting. Several experimental vaccines for
humans based upon live-attenuated virus, purified pro-
tein, viral vectors, or DNA plasmids are under develop-
ment (see reviews [19-21]) although none has advanced
beyond phase II. In theory, WNV E DIII protein is an
attractive target for vaccine development because many
strongly protective MAbs (in vitro and in vivo) against
flaviviruses, including WNV have been localized to this
region DIII (reviewed in [22]). Moreover, previous studies
have demonstrated the recombinant WNV DIII is a plau-
sible vaccine candidate when administered as a recombi-
nant protein [23], but less effective when expressed from
a DNA plasmid [24]. In this study, we developed candi-
date WNV DNA vaccines with greater immunogenicity
and protection using DIII or truncated E proteins conju-
gated to the molecular adjuvant P28.
Materials and methods
Virus and cell lines
WNV (TX114 strain), isolated from a blue jay in Texas in
2002 was used for all studies except for the passive anti-
body transfer experiment. The virus was propagated once
in Vero cells, aliquotted, and then frozen at -80°C. For the
passive antibody transfer experiments, the lineage 1 New
York WNV strain 3000.0259 that was isolated in 2000 was
passaged once in C6/36 Aedes albopictus cells to generate
an experimental stock. 293T (human embryonic kidney)
and Vero (African green monkey kidney) cells were main-
tained in DMEM with 10% FBS and 1% penicillin/strep-
tomycin (P/S). Raji cells stably expressing DC-SIGNR
were maintained as described [25].
Construction and expression of DNA vaccine plasmids
The WNV prM/E eukaryotic expression vector, pCBWN,
has been previously described [26] and encodes the prM
and E gene segments (accession number DQ211652)
from the strain NY99-6480 strain [26]. To generate an
Ecto E DNA vaccine, the glycine residue at position 706
was converted by mutagenesis to a TAG stop codon (Fig.
1A) [27]. The DIII of E (amino acids 296-415) was cloned
in frame with the tPA leader sequence in pTR600 (Fig.
1A). A second set of plasmids were constructed to
express Ecto E or DIII fused in frame with P28 [18,27].
Each gene sequence encoding for two functional copies of
P 2 8  w a s  c l o n e d  a t  t h e  3 '  e n d  o f  E c t o  E  o r  D I I I  u s i n g
unique restriction endonuclease sites. A BamHI restric-
tion endonuclease site was introduced using site directed
mutagenesis immediately 5' to the TAG stop site. A (Gly4-
Ser)2 linker was cloned in between each P28 gene. All
DNA vaccine plasmids were amplified in Escherichia coli,
purified using anion-exchange resin columns (Qiagen,
Valencia, CA) and stored at 20°C in dH2O. Plasmids were
verified by appropriate restriction enzyme digestion and
sequencing.
293T cells were transfected with 30 μg of DNA using
Lipofectamine 2000 according to the manufacturer's
instructions (Invitrogen, Carlsbad, CA). Cell culture
supernatants were collected 48 hrs post-transfection.
Approximately 1.5% of sample volume was loaded onto a
10% polyacrylamide/SDS gel. The resolved proteins were
transferred onto a Immobilon PVDF membrane (Milli-
pore, Temecula, CA) and incubated with a 1:5000 dilu-
tion of the WNV specific monoclonal antibody (mAb
8150, Chemicon, Temecula, CA) in PBS containing 0.05%
Tween-20 and 5% nonfat dry milk. After extensive wash-
ing, bound antibodies were detected using a 1:10,000
dilution of horseradish peroxidase-conjugated goat anti-
mouse antiserum, and visualized by chemiluminescence
(Western Lightning™, Perkin Elmer, Waltham, MA).Dunn et al. Virology Journal 2010, 7:95
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Figure 1 Schematic diagram of constructs and expression of vaccine plasmids. A. A diagram of the WNV genome is shown in the center, and 
the segments of the genome used in the vaccine constructs are shown above (DIII-modified) and below (prM/E-modified). The construct expressing 
prM/E was previously described [26]. The DIII region of the E gene (amino acids 586-705) was cloned downstream of the tpA leader sequence, and in 
some cases, P28 was also cloned in frame and directly after the 3' end of the DIII gene. An artificial BamHI site and stop codon was engineered at po-
sition 705 in the E gene to create the truncated Ecto E gene, and P28 was cloned into the Ecto E construct using the BamHI site to create the Ecto E-
P28 construct. B. Supernatants from 293T cells transiently transfected with plasmid DNA were assessed by SDS-PAGE and Western blot. The mem-
brane was probed by with the DIII-specific monoclonal antibody, 7H2. Lane 1: DIII-DNA; Lane 2: DIII-P28-DNA; Lane 3: prM/Ecto E-DNA; Lane 4: prM/
Ecto E-P28-DNA; Lane 5: prM/E-DNA; Lane 6: P28-DNA only; Lane 7: Vector DNA only.
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Virus titrations and immunohistochemistry
All virus titrations were performed on Vero cell monolay-
ers. Briefly, cells were incubated with indicated serial
dilutions of virus or mouse serum for 1 hour at 37°C. Sub-
sequently, the virus/serum inocula were removed and
replaced with a semi-solid overlay of carboxy-methylcel-
lulose in OptiMEM or 1% low melting point agarose (Sea-
Plaque) in α-MEM (Invitrogen) supplemented with 3 or
4% FBS. Cultures were incubated for 24-72 hours prior to
fixation with a 50:50 v/v mixture of methanol and acetone
or 10% formadehyde. For plaque assays, staining was per-
formed with 1% (w/v) crystal violet in 20% ethanol and
scored visually on a light box. For focus formation assays,
foci were visualized by immunohistochemistry.
Immunohistochemistry was performed on fixed and
dried cell monolayers by first rehydrating with 3% FBS in
PBS (blocking buffer) for 1 hour, then replacing the media
with a monoclonal antibody specific to WNV E protein
(7H2; BioReliance Corporation, Rockville, MD) diluted in
blocking buffer and incubated for at least 1 h. The pri-
mary antibody solution was removed and monolayers
were washed thrice in PBS prior to adding the goat anti-
mouse secondary antibody conjugated to peroxidase
diluted in blocking buffer. After 1 h, monolayers were
washed thrice in PBS again. WNV-infected cells were
visualized by adding the peroxidase substrate (Enzo Diag-
nostics, Farmingdale, NY).
Vaccination and Viral Challenge
Female C57BL/6 mice (n = 5-8 mice per group; aged 6-8
weeks) were purchased from Harlan Sprague Dawley,
(Indianapolis, IN, USA), immunized with each DNA vac-
cine plasmid intramuscularly (IM, 50 μg DNA injection
into thigh) or by gene gun (particle bombardment with 2
μg DNA coated on gold bullets) and then boosted with
the same dose on weeks 3 and 6. In some cases 0.2 μg or
0.02 μg of vaccine plasmid as a dose response was admin-
istered in a mixture of vector plasmid to keep a total of 2
μg total DNA vaccine. Blood was collected from anesthe-
tized mice via the retro-orbital route on weeks 5 and 8
post vaccination, then centrifuged at 6000 rpm for 10 min
to separate the serum. Sera were transferred to new vials
and frozen at -20°C.
For challenge, naïve or vaccinated mice administered
1000 focus forming units (FFU) of WNV (TX114 strain)
in a volume of 0.1 ml by the intraperitoneal route. WNV
was diluted in a filtered solution of 10% fetal bovine
serum (FBS) in phosphate buffered saline (PBS) prior to
the mice infections (diluents). Mice were weighed daily to
determine percent weight loss, and monitored to deter-
mine the severity of sickness. Moribund mice (severe
lethargy, hunched posture and ruffled fur) were eutha-
nized by CO2 asphyxiation and recorded as dead for the
next day. All mouse experiments were performed in
accordance and with approval of the Washington Univer-
sity or University of Pittsburgh Animal Studies guidelines
under BSL-3 conditions.
Passive transfer of antiserum to naïve mice
Five week old C57BL/6 mice (Jackson Laboratories) were
infected by subcutaneous route with 10 2 PFU of WNV
3000.0259 diluted in Hank's Balanced Salt Solution con-
taining 1% heat-inactivated FBS. For antibody protection
studies, one day prior to infection mice were treated by IP
injection with indicated amounts of immune (gene gun
vaccinated mice) or naïve serum diluted in 100 μl PBS.
Mice were monitored daily for 21 days for morbidity and
mortality.
Enzyme-Linked Immunoabsorbant Assay (ELISA)
A quantitative ELISA was performed to assess anti-DIII
specific IgG in serum of vaccinated mice. Individual wells
of a 96 microtiter plate were coated overnight at 4°C with
WNV DIII proteins produced from transfected 293T cells
and then blocked (25°C for 2 hr) with PBS supplemented
with Tween-20 (0.05%) and nonfat dry milk (5%). Each
serum sample was serially diluted and incubated (25°C
for 2 hr). Following serial washes with PBS Tween-20
(0.05%), samples were incubated (25°C for 1 hr) with HRP
conjugated goat anti-mouse IgG (1:5000) or one of four
IgG subclasses (IgG1, IgG2a, IgG2b, or IgG3) (Southern
Biotechnology, Birmingham, AL) diluted in PBS Tween-
20 (0.05%) and nonfat dry milk (5%). Unbound antibody
was removed and after additional washes samples were
incubated with TMB substrate, and the colorimetric
change was measured as the optical density at 405 nm
using a plate reader (Biotek Powerwave XS, Winooski,
VT USA). The O.D. value of the age-matched naïve sera
was subtracted from the OD values of the antisera from
the vaccinated mice. Results were recorded as the geo-
metric mean titer (GMT) ± the standard error of the
mean (SEM).
Focus Neutralization Reduction Assay (FRNT)
Sera from individual mice were heat inactivated at 56°C
for 30 min. In some cases, sera from moribund or surviv-
ing mice following WNV infection were pooled. Pooled
sera were diluted 1:10 in DMEM supplemented with 1%
FBS, P/S and HEPES, and serially diluted 2-fold thereaf-
ter. Pooled naïve sera from uninfected, unvaccinated
C57Bl/6 mice were used as a negative control. The 7H2
antibody, which neutralizes WNV in tissue culture [16],
was diluted in naïve mouse sera and used as a positive
control. Each dilution was incubated in an equal volume
of media containing WNV for 1 h at 37°C. The virus-anti-
body solutions were then placed in duplicate wells in a
24-well plate containing a confluent Vero monolayer and
incubated at 37°C for 1 h. Monolayers were rinsed free ofDunn et al. Virology Journal 2010, 7:95
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unbound virus-antibody solution, rinsed an additional
time with PBS, and then covered with the CMC overlay.
After 48 hours, monolayers were fixed with a 50:50 v/v
methanol and acetone solution. WNV foci were detected
by immunohistochemistry as described above. Titer was
determined as the dilution in which there was 50%
(FNRT50) or 80% (FRNT80) or greater reduction in the
number of WNV foci by immunohistochemical staining.
Results
Construction of WNV Vaccine Plasmids
DNA plasmids were constructed that contained either
the complete E gene (in context with the precursor viral
gene prM "prM/E") or portions of the E gene (ectodomain
(Ecto) or domain III (DIII)) (Fig 1A). A second set of plas-
mids was generated with these same gene sequences con-
jugated to two copies of the molecular adjuvant P28 to
enhance antibody responses to the conjugated antigen
(Fig. 1A). All of these gene cassettes were cloned directly
downstream of a cytomegalovirus promoter to drive effi-
cient transcription. Each plasmid efficiently expressed
the E gene insert in transiently transfected 293T cells as
determined by Western blot of clarified cell supernatant
with a WNV-specific anti-E MAbs (Fig 1B). DNA plas-
mids expressing DIII only produced a protein ~10-20 kD
in size. The addition of P28 resulted in an expressed pro-
tein of ~30 kD (Fig 1B; lanes 1 and 2). Ecto E (~65 kD)
and Ecto E-P28 (~70 kD) were efficiently secreted into
the supernatants of transiently transfected cells (Fig 1B;
lanes 3 and 4). In addition, a 65 kD protein representing E
was detected in supernatants from cells transiently trans-
fected with DNA expressing the prM/E gene cassette,
which produces subviral particles (SVPs) (Fig 1B; lane 5).
As expected, mock-transfected or vector-only transfected
cell supernatants showed no reactivity with WNV anti-E
MAbs.
The molecular adjuvant P28 enhances the anti-WNV 
antibody response
Mice were vaccinated with the panel of DNA vaccines via
one of two routes: gene gun (GG) or intramuscular (IM)
at weeks 0, 3, and 6. On week 8, serum samples were col-
lected and the anti-WNV DIII antibody levels were tested
by ELISA from individual clarified sera samples (Fig. 2).
C57BL/6 mice immunized with all of the DNA plasmids
via the gene gun route developed high titers of anti-WNV
DIII antibodies. In contrast, mice vaccinated by an intra-
muscular route with DIII-DNA had significantly lower
total IgG titers that were significantly enhanced by conju-
gation of P28 (Fig. 2A). The enhancement effect was
observed following gene gun administration of plasmids
only at lower doses of vaccine (Fig 2B). Mice vaccinated
IM with Ecto E, Ecto E-P28 or prM/E developed similar
titers (Fig 2A).
To characterize further the immune response elicited
by these vaccines, the IgG subtypes of the elicited anti-
DIII antibodies were determined (Table 1). Gene gun
DNA vaccination elicited primarily a T-helper (Th)-2
(characterized by IgG1 isotype), whereas DNA plasmids
administered intramuscularly elicited more of a Th-1
response (characterized by IgG2 isotype). C57BL/6 mice
immunized by gene gun with DIII- or DIII-P28-DNA
elicited predominately IgG1 and IgG2b. Similar antibody
isotypes were elicited with Ecto E and Ecto E-P28
expressing plasmids. Interestingly, the prM/E plasmid
elicited a broader IgG isotype profile via both ID and IM
Figure 2 Vaccine elicited anti-DIII antibodies. Total IgG titers were 
measured by ELISA on WNV DIII-coated plates from mice vaccinated ID 
or IM with DNA plasmids encoding sections of the WNV E gene, with 
or without molecular adjutant P28 on week 8. Each dot represents an 
individual mouse. Undetectable antibody titers were arbitrarily as-
signed a titer of 1. Error bars denote the standard error within the sam-
ples with a measurable titer. Representative data from 1 of 2 
experiments shown. A 2-way unmatched ANOVA with a Bonferroni 
post-test was used to determine the significance of the data between 
groups, which is denoted by asterisks; * P < 0.05, ** P < 0.01, *** P < 
0.001.
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routes and included anti-DIII antibodies of the IgG2c sub-
class.
Protection of mice against lethal WNV challenge
At week 10 (4 weeks from the final vaccination), C57BL/6
mice were challenged with a lethal dose (103 FFU) of
WNV. All unvaccinated and 80% of vector-only vacci-
nated mice (IM) infected with WNV died by day 11 post-
challenge (Fig. 3). The vector-only vaccinated mouse that
survived challenge nonetheless showed signs of morbid-
ity (hunchback posture and fur ruffling) and lost ~15% of
body weight, but recovered by 1 month post infection
(Fig. 4). All mice vaccinated with the prM/E plasmid con-
struct survived lethal challenge (Fig. 3) and did not lose
Figure 3 WNV challenge of vaccinated mice. Mice that were vaccinated with indicated plasmids were challenged with 103 FFU of WNV and as-
sessed daily for survival. Mice that were moribund were euthanized and counted as dead the following day. MOCK-challenged mice, which were in-
jected with diluent only, did not die or show signs of illness, and are not shown on the survival curves. The results are pooled from at 5 mice.
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Table 1: Anti-DIII Antibody Isotypes
C57BL/6
Gene Gun IgG1 IgG2a* IgG2b IgG2c
DIII 0.44 N.A. 0.18 0.00
DIII-P28 0.43 N.A. 0.24 0.00
Ecto E 0.41 N.A. 0.19 0.00
Ecto E-P28 0.38 N.A. 0.12 0.01
prM/E 0.44 N.A. 0.36 0.18
C57BL/6
Intramuscular IgG1 IgG2a IgG2b IgG2c
DIII 0.13 N.A.** 0.01 0.04
DIII-P28 0.41 N.A. 0.14 0.02
Ecto E 0.23 N.A. 0.08 0.00
Ecto E-P28 0.23 N.A. 0.04 0.01
prM/E 0.25 N.A. 0.20 0.11
*IgG2a isotype not expressed in C57BL/6 mice.
**N.A. = Not applicable since the IgG2a subtype is not expressed in C57BL/6 mice.Dunn et al. Virology Journal 2010, 7:95
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weight, regardless of the vaccination route. In general,
mice vaccinated by gene gun had higher rates of survival
and less weight loss compared to mice vaccinated intra-
muscularly. Eighty percent of mice vaccinated ID with
DIII-DNA survived challenge with little weight loss (Fig.
3A and 4) wher eas, no mice vaccina t ed IM wit h DIII-
DNA survived challenge (Fig. 3B, p < 0.004). All of these
mice lost weight prior to succumbing to infection (Fig.
4C). Conjugation of P28 to DIII enhanced the survival
rate to 60% when the DNA was administered IM (Fig. 3B,
p < 0.046). Interestingly, the disparity in survival between
ID and IM vaccination routes was also apparent in mice
vaccinated with Ecto E DNA (Fig. 3). Eighty percent of
m i c e  v a c c i n a t e d  I D  o r  I M  w i t h  E c t o  E - D N A  s u rv i v e d
challenge, and conjugation of P28 to Ecto E increased the
survival rate (100%) of ID-vaccinated animals, but slightly
decreased rate in IM-vaccinated mice (60%, Fig 3).
Although these survival results were not statistically dif-
ferent between these groups, survival did correlated with
weight loss, as mice that lost more weight had the highest
morbidity and mortality (Fig. 4).
To determine if protection against WNV challenge pro-
spectively correlated with a reduction in viremia, the sera
at day 2 post-infection in each vaccine group was ana-
lyzed for infectious virus by a focus forming assay. Vacci-
nated C57BL/6 mice that survived infection (Fig. 5) had
viremia that was at or below the limit of detection at day 2
post-challenge. With the exception of one mouse vacci-
nated with the Ecto E vaccine, all mice that died had a
viremia at day 3 of greater than 4 × 102 FFU/ml (Fig 5).
Neutralization titers
Sera from mice immunized with the DNA vaccines were
assayed for the ability to neutralize WNV infection in cell
culture (Table 2). Serum samples collected at week 8 and
again at 1 month post challenge (week 14 of study) were
divided into two groups: (1) mice that survived subse-
quent lethal challenge and (2) mice that did not survive
challenge (obtained from terminally moribund mice
immediately prior to euthanasia). Mice vaccinated with
any of the DNA vaccines by gene gun that survived chal-
lenge had high neutralizing titers at eight weeks (1/80-1/
320; FRNT80), whereas those that died from challenge
had lower titers <1/20 (Table 2). In contrast to gene gun
vaccination, only mice vaccinated with prM-E DNA
intramuscularly had high neutralizing titers, which again
correlated with survival. Mice vaccinated via gene gun
with DNA plasmids expressing DIII, Ecto E, or these
immunogens conjugated to P28 had titers <1/20
(FRNT80) did not survive infection. Similar results were
observed using a FRNT50, albeit the titers were higher
than FRNT80. Regardless of the route of vaccination, mice
that survived challenge exhibited an immunological
boost by 14 weeks since neutralizing titers rose following
infection (FRNT80; 1/320-1/1280).
Passive sera transfer protects mice from virus infection
Although several mice immunized with DIII plasmids
survived infection, it remained unclear mechanistically
whether this was due to antibodies or possibly, memory
CD4+ and CD8+ T cell responses To determine if anti-
DIII antibodies alone could afford protection against
WNV infection, pooled antiserum from each gene gun
vaccinated group was transferred intraperitoneally into
naïve 5 week-old C57BL/6 mice, which were then chal-
lenged with 102 PFU of WNV (Fig. 6). Fifty to seventy
percent of mice administered sera from mice vaccinated
with DIII, Ecto E or Ecto E-P28 survived challenge 21
days post-infection. Sera from mice vaccinated with DIII-
P28 or prM-E showed greater (80-90%) survival com-
pared to DIII alone, although this did not attain statistical
significance. As expected, nearly all mice (10% survival))
Figure 4 Weight loss curves of WNV-infected vaccinated mice. 
The weights of mice vaccinated by the GG (A) and IM (B) routes and 
challenged with 103 FFU of WNV were recorded daily. Dead and mori-
bund mice were included in the weight loss curves on the day of 
death, but not after. The daily weight of each mouse was compared to 
her weight the day of challenge, and data are shown as the average 
percentage of initial weight for each cohort. The color scheme is iden-
tical for both panels. Error bars represent the standard error for all sam-
ples available at that time point.
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administered naïve sera succumbed to virulent WNV
infection.
Discussion
Although it has been a decade since the emergence of
WNV in North America, there remains no effective,
licensed vaccine to combat WNV induced disease in
humans. Although candidate vaccines have not advanced
beyond phase I and II clinical trials for humans [19,28],
there are currently approved inactivated and DNA vac-
cines licensed for use in horses and geese. Since neutral-
izing antibodies may serve as a primary protective
function against challenge [5], recent vaccine strategies
have focused on using the ectodomain of E or different
domains within E to elicit neutralizing anti-WNV anti-
bodies [23,24,26,29-33]. Recent attention has been
focused on DIII as a potential immunogen because struc-
tural and functional studies suggest that many protective
antibodies against WNV recognize this highly conserved
epitopes within this region. Some DIII-specific neutraliz-
ing antibodies are particularly potent in blocking viral
fusion and escape from the endosome [34,35].
In this study, a series of DNA-based vaccines expressing
the full length E, Ecto E or the DIII domain of E were
fused to the molecular adjuvant P28 to enhance antibody
titers. The addition of P28 to DIII or Ecto E increased the
anti-DIII IgG antibody titer in C57BL/6 mice. However, a
high anti-DIII antibody titer was not sufficient to com-
pletely protect against WNV infection. Mice vaccinated
with nearly all gene gun delivered vaccines elicited similar
high-titer anti-DIII antibodies, however, only the prM/E
and Ecto E-P28 vaccinated mice were completely pro-
tected from lethal challenge.
Figure 5 Viremia of protected and unprotected mice following WNV challenge. Sera taken from the blood of three mice from each group 2 days 
after infection were titrated on Vero cells to determine levels of virenia. Each point represents the titer from one mouse; black and red dots denote 
animals that survived and died, respectively. The dashed line represents the limit of detection (LOD) for this assay, which was 4 × 102 FFU/ml of serum. 
Mice with a viremia less than the LOD were arbitrarily shown as dots at the bottom of the graph.
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Several studies have previously demonstrated the
immunogenicity of the E protein DIII domain [23,29,36-
40]. However, immunization of purified recombinant
DIII has not consistently elicited high-titer neutralizing
antibodies, thereby indicating that the neutralizing
epitope may be poorly immunogenic in the context of a
s o l u b l e  p r o t e i n ,  o r  t h a t  a dominant non-neutralizing
epitope is present on the soluble DIII but is not exposed
in the context of the virion. Expression of DIII from a
DNA vaccine plasmid also has been less than optimal in
eliciting neutralizing antibodies. The results from our
study suggest that DIII may be less efficiently secreted
from transfected cells (data not shown), which may in
part explain the lowered immune responses seen during
vaccination with DIII alone. Conjugation of P28 may
assist DIII protein secretion from transfected cells, help-
ing to explain why the P28-conjugated vaccines elicited
higher DIII-specific antibody titers (by ELISA) and
higher protection against lethal challenge than non-con-
jugated vaccines in some cases. Although the use of
molecular adjuvants, such as P28, did not skew the anti-
body repertoire, they did increase the efficacy of the
response of DIII-based DNA vaccines. An analogous
increase in overall titer was observed when JEV or WNV
DIII was linked to IL-15 [24].
Prospective studies have shown a direct correlation
between the level of neutralizing antibody prior to chal-
lenge, the magnitude of viremia, and survival rates in
m i c e  [ 5 ] .  N o n e t h e l e s s ,  s o m e  m i c e  v a c c i n a t e d  I M  w i t h
DIII-P28, Ecto E, and Ecto E-P28 were protected from
challenge despite the absence of high-titer pre-challenge
neutralizing antibodies (FRNT80 ≤ 20). Although further
mechanistic studies are required, we suggest three possi-
ble explanations: (a) non-neutralizing antibodies are pro-
tective through complement and/or Fc?R-dependent
functions. Indeed, we have previously seen this pheno-
type with mAbs against WNV NS1, which is absent from
the virion [41]; (b) the in vitro neutralization assay does
Table 2: FRNT and Mouse Survival
Sample Group Survival [# 
pooled/# in 
vaccinated 
group]
FRNT50* FRNT80 FRNT50 FRNT80
GG Pre-infection Post-infection
1 DIII Yes [4/5] 640 80 2560 320
2D I I I N o  [ 1 / 5 ] < 2 0 < 2 0
3 DIII-P28 Yes [3/5] 320 80 1280 320
4 DIII-P28 No [2/5] 40 20
5 ectoE Yes [4/5] 320 320 2560 640
6e c t o E N o  [ 1 / 5 ] 4 0 < 2 0
7 ectoE-28 Yes [5/5] 640 320 2560 640
8 prM/E Yes [5/5] 320 160 1280 640
9n a ï v e N o  [ 5 / 5 ] 2 0 < 2 0
IM Pre-infection Post-infection
10 DIII No [5/5] <20 <20
11 DIII-p28 Yes [3/5] 20 <20 1280 640
12 DIII-p28 No [2/5] 20 <20
13 ectoE Yes [4/5] 40 20 2560 1280
14 ectoE No [1/5] 20 <20
15 ectoE-p28 Yes [3/5] 40 20 2560 640
16 ectoE-p28 No [2/5] <20 <20
17 prM/E Yes [5/5] 320 160 2560 640
18 vector Yes [1/5] 40 <20 640 80
19 vector No [4/5] <20 <20
* Titers shown as the reciprocal titerDunn et al. Virology Journal 2010, 7:95
http://www.virologyj.com/content/7/1/95
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not accurately reflect possible neutralization of virus in
vivo. Antibodies that block virus attachment of one cell
type (e.g., Vero cells) may not function effectively against
a second more physiologically relevant cell type (e.g., den-
dritic cells). Of note, differences in neutralization potency
among cell types were observed with mAbs against
epitopes in DI and DII of WNV E protein [42]; and/or (c)
T cell responses to peptide epitopes in the E protein inde-
pendently contribute to protection. The isotype of the
polyclonal antibody in part determines the effector func-
tions of the anti-WNV antibodies and identifies the T
helper cell bias (required for antibody class switching).
Antibodies of the IgG2a/c and IgG2b subclass fix comple-
ment proteins C1q and C3 and can opsoznize and inhibit
flavivirus infection [43-45]. IgG2a/c bind FcγRI with high
avidity facilitating enhanced uptake of virus-antibody
complexes by macrophages. The predominant IgG iso-
type detected was IgG1 indicating a Th2 bias. However,
IgG2b was detected in almost all vaccine groups, with a
strong level of this isotype and IgG2c detected in prM/E
vaccinated mice (Table 1), which may help to explain the
effectiveness of these vaccines. C57BL/6 mice do not
express IgG2a, if this isotype was associated with protec-
tion, could have been an explanation for the inconsistent
protection with these vaccines.
C3d and P28 have been used as effective molecular
adjuvants to elicit high titer antibodies against other
pathogens [18,27,46-53]. This study extends this platform
to WNV, and likely other flaviviruses due to the similarity
in E protein structure and function within the genus.
Interestingly, gene gun administration of DNA plasmids
elicited higher titer antibody responses and broader pro-
tection against WNV infection than through the IM
route. For mice that were vaccinated gene gun, there was
a clear correlation between viral neutralization titers and
survival. This correlate was less apparent in IM-vacci-
nated mice, with most mice surviving infection having
low neutralization titers. This discrepancy in survival
may be explained, at least in part, by the types of cells that
internalize the DNA plasmids and express and/or present
these antigens. Muscle cells and infiltrating appear to
internalize plasmid DNA following IM administration
[54]; these cell types may not efficiently secrete these viral
proteins. Gene gun differs from intramuscular or intrad-
ermal injection of DNA with a needle and syringe in that
it results in direct delivery of the vaccine into the intracel-
lular environment [55]. Gene gun delivery of DNA plas-
mids is complex and can involve both non-professional
antigen presenting cells (APC), such as keratinocytes and
professional APCs, such as Langerhans cells [56] and
[57]. Compared to other routes of delivery, gene gun
inoculations can induce both antibody and CD8+ T cell
responses with substantially lower doses of DNA. The
effectiveness of this system is likely related to the use of a
delivery technology that deposits DNA directly into cells
[55]and [57] as well as the immune competence of the
epidermis as a delivery site [58] and [59]. Skin cells likely
traffic to the draining lymph nodes where the expressed
proteins are processed and presented to immune cells
[60,61].
Passive transfer studies with serum from vaccinated
mice to naïve mice established that antibody generated
after immunization was sufficient for protection. The
percentage of mice surviving challenge after passive
transfer appeared similar to the percentage of vaccinated
mice that survived after direct challenge. Although fur-
ther studies with depleting anti-CD4 and CD8 mAbs are
required to precisely evaluate the contribution of T cells
to protection in these vaccinated mice, it is noteworthy
that for C57BL/6 mice, the immunodominant H-2b T cell
epitopes for WNV fall outside of DIII [62-64].
In general, immunogens based upon Ecto E elicited bet-
ter protective responses than those based upon DIII.
Likely, WNV E proteins contain multiple neutralizing
epitopes in separate domains and therefore, a broader
panel of neutralizing antibodies can be generated. The
prM/E plasmid produces SVPs, which are effective
immunogens since they contain conformationally rele-
vant prM and E protein [14,65,66]. However, Ecto E-P28
elicited comparable immune responses and protection as
prM/E when delivered ID, indicating that DNA vaccina-
tion can be as effective as the prM/E vaccines currently
used for animal vaccines.
The results from the WNV vaccines described in this
report indicate that DIII can be an effective immunogen
when expressed from a DNA plasmid, when conjugated
to a molecular adjuvant like P28 and delivered as a gene
Figure 6 Passive transfer of antibody from vaccinated mice pro-
tects against lethal WNV challenge. Five week-old C57BL/6 mice 
were pre-treated with 25 μl of serum from the indicated vaccinated 
mice or naïve animals at day -1 by intraperitoneal injection. On day 0, 
mice were infected with 102 PFU of WNV by subcutaneous route and 
monitored for survival. All vaccinated mice showed statistically signifi-
cant protection (P < 0.05, log rank test) compared to mice receiving na-
ïve sera. Data reflect two independent experiments with a total of n = 
10 mice per arm.
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gun based DNA vaccine. The mechanism of delivery
could account for the induction of protective responses.
Gene gun elicits a T cell helper type 2 (Th2) bias, as indi-
cated by the predominance of elicited IgG1, which may be
just as an important factor in eliciting neutralizing anti-
bodies as the immunogen epitopes. Nonetheless, our
studies have not yet shown that DIII elicits superior neu-
tralizing responses when conjugated to a C3d molecular
adjuvant. Although further studies are warranted, we
speculate that this is due to the presence of immunodom-
inant non-neutralizing epitopes on the A-B loop that is
normally solvent inaccessible [67]. Reverse genetic stud-
ies are underway to create DIII variants that lack this
immunodominant epitope and thus, focus the immune
response on the lateral ridge epitope, which is recognized
by highly neutralizing antibodies. By combining this
molecular approach with the addition of P28, alone or
with other vaccine modalities, we believe it will be possi-
ble to create a catalogue of safe immunogens that elicit
high-titer neutralizing antibody responses against all fla-
viviruses.
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